期刊
CHEMICAL BIOLOGY & DRUG DESIGN
卷 84, 期 2, 页码 216-222出版社
WILEY
DOI: 10.1111/cbdd.12307
关键词
continuous fluorescence assay; drug design; novel inhibitor; secretory phospholipase A(2); virtual screen
资金
- Ministry of Science and Technology of China
- National Natural Science Foundation of China
Human non-pancreatic secretory phospholipase A(2) was reported to be associated with inflammatory diseases and considered as a potential drug target for inflammation and other related disease treatment. Although many human non-pancreatic secretory phospholipase A(2) inhibitors were reported, few entered into the drug development stage due to various problems. In this study, we discovered seven novel human nonpancreatic secretory phospholipase A(2) inhibitors using virtual screen. Of the 99 compounds tested by continuous fluorescence assay, seven are potent human nonpancreatic secretory phospholipase A(2) inhibitors with micromolar IC50 values. Typical molecules include 9-fluorenylmethoxycarbonyl protected alpha-phenylalanine derivatives and azo compounds, which may serve as novel scaffold for developing potent human non-pancreatic secretory phospholipase A(2) inhibitors. These compounds bind to human non-pancreatic secretory phospholipase A(2) by interacting with the catalytic calcium ion and the hydrophobic regions in the substratebinding pocket.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据